(Q37576546)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1 reference

1 reference

1 reference

corrigendum / erratum

Erratum to “A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile” by Czajka et al. [Vaccine 27 (47) (2009) 6504–6511]

0 references

author

Susanna Esposito

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Hanna Czajka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Volker Schuster

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Fred Zepp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Martine Douha

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Paul Willems

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

7 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

6504-6511

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Decline in mortality due to varicella after implementation of varicella vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Varicella disease after introduction of varicella vaccine in the United States, 1995-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Varicella vaccination in Japan, South Korea, and Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Varicella vaccination in Europe: are we ready for a universal childhood programme?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

MMR vaccine: review of benefits and risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Mumps and rubella eliminated from Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Loss of vaccine-induced immunity to varicella over time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Review of the Varilrix varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Efficacy of high-titer live attenuated varicella vaccine in healthy young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Varicella vaccine effectiveness during an outbreak in a partially vaccinated population in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Varicella vaccination of health-care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Reactogenicity to a live attenuated varicella vaccine in Canadian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Use of a computerized database to study the effectiveness of an attenuated varicella vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Three-year follow-up of protection rates in children given varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Aseptic meningitis after measles, mumps, and rubella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.076

10.1016/J.VACCINE.2009.07.076

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19665608%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference